DAKOTA...our first "Basher" obviously without any knowledge.
Congrats that you are our first board "Basher" unfortunately you are very wrong, as I have been in the stock for 5 years, look for a small financing in the $2.50 to $3 range maybe 5 to 8 million shares raising 15 to 20 million.
Our debt is gone, less than $500,000, this first small financing which is going to take us into 2015 will only dilute the stock to the tune of 22 to 25 million outstanding, with the float being very tight.
Everyone who participated in the debt restructuring have Tapimmune's best interest at heart, expect little selling.
News that will be forthcoming will propel the stock much, higher, I personally will be looking for shorts like you to try to drive stock down because along the course those propellants will help our stock tremendously.
Do your DD this is one of the tightest restructuring that I have seen, with what is going to play out to be maybe one of the greatest stories in a long time.
Bring your friends, short at will... we actually welcome all comers.
They have the Technology, they are in the space, multi billion market. Will go as a stand alone, or there will be many Big Pharma's looking to acquire our Technology. All data has been peer reviewed, this first news yesterday is just the tip of the iceberg.
They will have no problem up listing to either NASDAQ, or NYSE, vaccine technology is best platform by far, interest behind the scenes is already gaining ground.
1. Financing small dilution, but needed to make more liquidity.
2. Up listing to larger exchange.
3. Multi billion dollar markets, with most comprehensive platform in many areas.
4. Great takeover target, but with their proprietary Technology will garner a big premium.
5. All data has been published in peer reviewed journals.
GLTA I believe that there already are many Big Pharma's, that have been watching our technology, but have not been able to participate because the OTC listing and the mess the stock was in.
Everything has changed and once the overall market gets wind of what is going on and the above mentioned catalysts Tapimmune will determine it's own destiny.
I am well invested and already profitable at this point, the game has not even started.
Buy on an weakness, going into the financing it may be the only chance to get your position in the just under 3 range, but because the float is so tight don't expect much, and it will only propel our positions higher...I will thank you in advance for that participation on your behalf..
Bashers will be battling for the scraps those of us that are aware of the story either have our positions or will be buying before additional news and market awareness fully addresses Tapimmune's potential.
DAKOTA: Look forward to proving you, the first basher of our stock wrong, good luck see you in 6 months.
STRONG BUY
